211 related articles for article (PubMed ID: 30271746)
1. The Genetics of Clinical Liver Diseases: Insight into the
Zhang X; Liu S; Dong Q; Xin Y; Xuan S
J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
[TBL] [Abstract][Full Text] [Related]
2. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
3. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
[TBL] [Abstract][Full Text] [Related]
4. TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease.
Chen LZ; Xia HH; Xin YN; Lin ZH; Xuan SY
J Clin Transl Hepatol; 2015 Dec; 3(4):265-70. PubMed ID: 26807382
[TBL] [Abstract][Full Text] [Related]
5. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
Milano M; Aghemo A; Mancina RM; Fischer J; Dongiovanni P; De Nicola S; Fracanzani AL; D'Ambrosio R; Maggioni M; De Francesco R; Fargion S; Berg T; Stickel F; Hampe J; Romeo S; Colombo M; Valenti L
Hepatology; 2015 Jul; 62(1):111-7. PubMed ID: 25820484
[TBL] [Abstract][Full Text] [Related]
7. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
8. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
9. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.
Liu Z; Que S; Zhou L; Zheng S; Romeo S; Mardinoglu A; Valenti L
Sci Rep; 2017 Aug; 7(1):9273. PubMed ID: 28839198
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes sex-specific effects associated with E167K coding variant in
Fan Y; Wolford BN; Lu H; Liang W; Sun J; Zhou W; Rom O; Mahajan A; Surakka I; Graham SE; Liu Z; Kim H; Ramdas S; Fritsche LG; Nielsen JB; Gabrielsen ME; Hveem K; Yang D; Song J; Garcia-Barrio MT; Zhang J; Liu W; Zhang K; Willer CJ; Chen YE
iScience; 2021 Nov; 24(11):103196. PubMed ID: 34746691
[TBL] [Abstract][Full Text] [Related]
11. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
12. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
Luo F; Oldoni F; Das A
Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
[TBL] [Abstract][Full Text] [Related]
13. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
14. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
15. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
[TBL] [Abstract][Full Text] [Related]
16. TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6.
Du S; Liao S; Liu S; Xin Y
J Clin Transl Hepatol; 2019 Mar; 7(1):27-31. PubMed ID: 30944816
[No Abstract] [Full Text] [Related]
17. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
18. Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variant.
Faccioli LA; Sun Y; Motomura T; Liu Z; Kurihara T; Hu Z; Cetin Z; Franks J; Stolz D; Ostrowska A; Florentino RM; Fox IJ; Soto-Gutierrez A
bioRxiv; 2023 Dec; ():. PubMed ID: 38187603
[TBL] [Abstract][Full Text] [Related]
19. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
20.
Liu S; Murakami E; Nakahara T; Ohya K; Teraoka Y; Makokha GN; Uchida T; Morio K; Fujino H; Ono A; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes NC; Imamura M; Aikata H; Chayama K
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]